BioSpace News Archive

Harbour BioMed (HBM) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application for a Phase 2 clinical trial of HBM9167, its humanized IgG1 monoclonal antibody targeting programmed death-ligand 1 (PD-L1), for the treatment of nasopharyngeal cancer (NPC

According to the Centers for Disease Control and Prevention, Medicare spent $36 billion in 2017 treating people with end-stage renal disease – the final stage of chronic kidney disease.

Photocure ASA, reported a revenue growth of 51% for the U.S. market in the fourth quarter of 2019, contributing to Hexvix/Cysview revenues of NOK 58.8 million and a recurring EBITDA of NOK 1.6 million.

Builds on Hikma’s leading position in nasal sprays and strong specialty salesforce

Sedana Medical AB announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona virus affected patients to two hospitals in Wuhan and Zhejiang, China.

Dr. Reddy’s Laboratories Ltd. announced the first-to-market launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, a therapeutic equivalent generic version of Vimovo® Delayed-Release Tablets approved by the U.S. Food and Drug Administration.

WuXi Diagnostics has successfully developed a series of COVID-19 detection products, including 2019-nCoV IgM Detection kit, 2019-nCoV IgM/IgG Detection Kit and 2019-nCoV Nucleic Acid Detection Kit.

NuVasive, Inc. announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.375% Convertible Senior Notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Hygiene and health company Essity has signed an agreement to acquire 75% of the Swedish medical solutions company ABIGO Medical AB.

Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma and Phase 1 ALLO-715 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma On-Track for Q2 2020 and Q4 2020, Respectively